Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IndividualfiledCriticalIndividual
Priority to DE1951W0004086priorityCriticalpatent/DE1632033U/en
Publication of DE1632033UpublicationCriticalpatent/DE1632033U/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Description
ßyffSJ1. s.'8eft1'f1tdor.. 1fSMMMSSMSSSKSKSaS<aS@ aa3aaa&sm@&Baa aä&e. ! mm w « x-wu v= $obouetI.. ... Butt" 11. .SsaSäaßsg ssiaeßseBMSaB.lasSäeaSßlss B EiEs8aßa8sa&&asssZYaSMas&iBs s sasasjasaeSss s anä&UMtaasssSLRN&e. age aas-nobol dle cm Abo-] eafSssgssge&ae es mate sssti'pluttenmmds auege. 1iObo1 t11o e ? le.'tta Sttm Ab-: äSsassss3s&b-3paaS. i'esKMiaa<as*sscl3ißsa sebseia&sjS3<saaea. st.jaassagsssSSascsaa MsiNaMsKStjsas saQasiSßAut *W Z"-e-t-M M-ist &W vi'tuEM. NC§ßt6d EE SSSS4.. t J'åpd. f88e whtL..... 8 Iñ éf : in e.. ce-s<meaes. m&s. a'isE&issKej&ssjjäaass& * Ba0, w=Mttn-t * Dw ze=-aMff@e-. eg'ea&'es0 Ist mwBssssssaMaajäKsasis&iesaeeaaJsHßw, Itt « LU a mg 0 OIU*. In be ; ZO=Otllor-,->14. 00 &Mut
etwu. d uber üm rzrurteli b 24egt ; =d beim InGeuetati d eem=* 1--% lo ewecraatei b =d aSgssMßahSaBsas ! &aSe !-=termtw me wn dmsBsasNSMKSE&tat sn gar c mf ; taen a ur pzatte a in mo e022um,SsaaaassKm1-at dm ger4cftt almeitlg-gebr-"-tm. mlant mmmw ama, * ctmleät #. to M tä, *" k102um Dmzekm ssssBa raaps ! 3sBs3ßE- 4 Ubæ s. b Ueg1 ; beim . 1ß In ses-eion S9taaäsae&&t11e ! t'tm a und e vm 4m1 F 1., mP1n'tte a m tt1e ñdbgGse1Ghæw sten.m xs iion : : IbM" artlOkt die rIa m1 t k1 t g un"1X doS odDr lobwom 3&-t in au i-mm =ru* trmc02n h=4 ueumt.., ... iSsaas <B3Ssms e9% UM idbui. 3aMaßig$ßa säage aasai&sSassbMß Biäsa3@saHgesM MSaa2er.dm plu= mt &4SMsFSKas& ßy ffSJ1. s.'8eft1'f1tdor .. 1f SMMMSSMSSSKSKSaS <aS @ aa3aaa & sm @ & Baa aä & e. ! mm w «x-wu v = $ obouet I. .. ... Butt "11.. SsaSäaßsg ssiaeßseBMSaB . lasSäeaSßlss B EiEs8aßa8sa & & asss ZY aSMas & iBs s sasas jasaeSss s anä & UMtaa sssSLRN & e. age carrion nobol dle cm subscription ] eafSssgssge & ae es mate sssti ' pluttenmmds auege. 1iObo1 t11o e? le.'tta Sttm Ab- : äSsassss3s & b-3paaS. i'esKMiaa <as * sscl3ißsa sebseia & sjS 3 <saaea. st. jaassagsssSSas csaa MsiNaMsKStjsas saQasiSß Aut * WZ "-etM M-ist & W vi'tu EM. NC§ßt6d EE SSSS 4 .. t J'åpd. f88e whtL ..... 8 Iñ éf: in e .. ce- s <me aes. m & s. a ' isE & issKej & ssjjäaas s & * B a 0, w = Mttn-t * Dw ze = - aMff @ e-. eg'ea &'es 0 is mw Bssss ssaMaajäK sasis & iesaeeaaJs Hßw, Itt «LU a mg 0 OIU *. In be; ZO = Otllor -, -> 14. 00 & courage to do sthu . d over üm rzrurteli b 24egt; = d at In Geuetati d eem = * 1 -% lo ewecraatei b = da SgssMßahSaBsas! & aS e ! - = termtw me wn dm sBsasNSMKSE & tat sn gar c mf; taen a ur pzatte a in mo e022um, SsaaaassKm 1-at dm ger4cftt almeitlg-gebr - "- tm. Mlant mm mw ama, * ctmleät #. to M ta, * "k102um Dmzek m ssssBa raaps! 3sBs3ßE - 4 Ubæ s. B Ueg1; at the . 1ß In ses-eion S9taaäsae && t11e! t'tm a and e vm 4m1 F 1., m P1n'tte am tt1e ñdbgGse1Ghæw sten. mx s iion:: IbM "artlOkt the rIa m1 t k1 tg un "1X doS orDr lobwom 3 & -t in au i-mm = ru * trmc02n h = 4 ueumt .., ... i Ssaas <B3Ssms e 9% UM idbu i. 3aMassig $ ßa saage aasai & sS assbMß Biäsa3 @ saHgesM MSaa 2er. dm plu = mt & 4 SMsFSKas &
Safety and Efficacy of Thymopentin in Zidovudine (AZT)-Treated Asymptomatic HIV-Infected Subjects with 200–500 CD4 Cells/mm3: A Double-Blind Placebo-Controlled Trial